Back to Search Start Over

BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OFBENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILDTYPEMETASTATIC COLORECTAL CANCER (MCRC) PATIENTS